embrace Active Scar Defense
Commercial- Indications
- Post-surgical scarring, Scar revision
Company intelligence / Profile preview
Neodyne Biosciences has developed the embrace® Active Scar Defense system—a polymer-based elastomeric dressing that reduces mechanical tension on healing incisions to minimize scar formation. Clinical studies have shown significant improvements in scar appearance for up to 12 months post-procedure compared with standard care. The product has been FDA cleared and commercially available since at least 2013. The company holds several international patents for its technology.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Neodyne Biosciences.